Korea’s Human Platelet Lysate (HPL) market is expanding, driven by growth in cell therapy and advanced biopharmaceutical development. In a significant development, Xcell Therapeutics has signed a distribution agreement with PL BioScience GmbH to supply HPL in the Korean market. This agreement is expected to enhance the availability of HPL, which is crucial for cell culture processes.

HPL is widely used in cell therapy and regenerative medicine, supporting cell proliferation and safety in various applications. Under the terms of the agreement, Xcell will distribute PL BioScience’s ELAREM Ultimate-FD PLUS, a product that leverages the benefits of HPL.

The global HPL market is projected to grow from approximately $600 million in 2024 to $2.4 billion by 2035, with an annual growth rate exceeding 15 percent. This growth is indicative of the increasing demand for innovative solutions in cell therapy and regenerative medicine.

Dr. Hatim Hemeda, a representative from Xcell, stated, “Xcell is an ideal partner with GMP production capabilities, cell culture media expertise, and a global network.” This partnership is seen as a strategic move to combine the core technologies of both organizations, enhancing their competitive edge in the market.

Additionally, PL BioScience holds a patent for gamma irradiation technology used in HPL, further strengthening the quality and safety of their products. Xcell Therapeutics also plans to co-develop a new media product with PL BioScience, aiming to broaden customer reach and strengthen long-term revenue growth.

As the partnership unfolds, industry observers are keen to see how this collaboration will impact the HPL market in Korea and beyond. The agreement not only signifies a commitment to innovation but also highlights the growing importance of HPL in modern therapeutic applications.